Deepcell co-founder Maddison Masaeli took an unexpected path from academic research to launching an AI-powered cell analysis platform. The company has raised close to $100 million in funding to support its mission. This includes a $73 million Series B round and an earlier $20 million Series A round. The company has entered into a research…
Deepcell’s REM-I platform marries AI with morphological analysis for drug discovery
From her early days as a research assistant at UCLA, to her work as a postdoctoral fellow at Stanford, Deepcell co-founder and CEO Maddison Mahdokht Masaeli has actively engaged in the field of biomedical engineering. Now, Masaeli and her team at Deepcell, a company she co-founded in 2017, are introducing a new strategy to drug…